Moreover, the CheckMate-026 trial revealed that a PD-L1 expression level of ≥ 50% failed to serve as a reliable predictor of the effectiveness of Nivolumab in first-line NSCLC treatment (ORR, 34% vs. 39%) (33). Here, CD274 is linked to non-small cell lung carcinoma.